{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T23:04:05Z","timestamp":1779663845917,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006014","name":"College of Medicine and Health Sciences, United Arab Emirates University","doi-asserted-by":"publisher","award":["12R270"],"award-info":[{"award-number":["12R270"]}],"id":[{"id":"10.13039\/501100006014","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"DOI":"10.1186\/s40246-026-00962-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:26:07Z","timestamp":1775895967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users"],"prefix":"10.1186","volume":"20","author":[{"given":"Areej S.","family":"Albawa\u2019neh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mais N.","family":"Alqasrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeina N.","family":"Al-Mahayri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"al dain Marzouka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilas","family":"Dabaghie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hamza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna Q.","family":"Khasawneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virendra","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husam","family":"Ouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-6618","authenticated-orcid":false,"given":"Bassam R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"962_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-11-248","author":"JA Friesen","year":"2004","unstructured":"Friesen JA, Rodwell VW. The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases. Genome Biol. 2004. https:\/\/doi.org\/10.1186\/gb-2004-5-11-248.","journal-title":"Genome Biol"},{"key":"962_CR2","unstructured":"Grundy SM, Feingold KR. Guidelines for the Management of High Blood Cholesterol. Endotext. 2000."},{"key":"962_CR3","doi-asserted-by":"publisher","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753). https:\/\/doi.org\/10.1016\/S0140-6736(10)61350-5.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"962_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph15020151","author":"Y Morofuji","year":"2022","unstructured":"Morofuji Y, Nakagawa S, Ujifuku K, Fujimoto T, Otsuka K, Niwa M, et al. Beyond Lipid-Lowering: Effects of Statins on Cardiovascular and Cerebrovascular Diseases and Cancer. Pharmaceuticals. 2022. https:\/\/doi.org\/10.3390\/ph15020151.","journal-title":"Pharmaceuticals"},{"key":"962_CR5","doi-asserted-by":"publisher","unstructured":"Ruscica M, Ferri N, Banach M, Sirtori CR, Corsini A. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc Res. 2022;118(17). https:\/\/doi.org\/10.1093\/cvr\/cvac020.","DOI":"10.1093\/cvr\/cvac020"},{"issue":"5","key":"962_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587","volume":"12","author":"C Reith","year":"2024","unstructured":"Reith C, Preiss D, Blackwell L, Emberson J, Spata E, Davies K, et al. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306\u201319. https:\/\/doi.org\/10.1016\/S2213-8587. (24)00040-8 PubMed PMID: 38554713.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"962_CR7","doi-asserted-by":"publisher","unstructured":"Alqasrawi MN, Al-Mahayri ZN, AlBawa\u2019neh AS, Khasawneh LQ, Dabaghie L, Altoum SM, et al. Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE\u2019s multiethnic population. Hum Genomics. 2025;19(1). https:\/\/doi.org\/10.1186\/s40246-025-00753-6. PubMed PMID: 40281622.","DOI":"10.1186\/s40246-025-00753-6"},{"key":"962_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2015.194","author":"DJ Betteridge","year":"2016","unstructured":"Betteridge DJ, Carmena R. The diabetogenic action of statins-mechanisms and clinical implications. Nat Reviews Endocrinol. 2016. https:\/\/doi.org\/10.1038\/nrendo.2015.194.","journal-title":"Nat Reviews Endocrinol"},{"key":"962_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-018-0995-6","author":"A Agarwala","year":"2018","unstructured":"Agarwala A, Kulkarni S, Maddox T. The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations. Curr Cardiol Rep. 2018. https:\/\/doi.org\/10.1007\/s11886-018-0995-6.","journal-title":"Curr Cardiol Rep"},{"key":"962_CR10","doi-asserted-by":"publisher","unstructured":"Sattar N. Statins and diabetes: What are the connections? Best Practice and Research: Clinical Endocrinology and Metabolism. Bailliere Tindall Ltd; 2023. https:\/\/doi.org\/10.1016\/j.beem.2023.101749. PubMed PMID: 36858834.","DOI":"10.1016\/j.beem.2023.101749"},{"issue":"1","key":"962_CR11","doi-asserted-by":"publisher","first-page":"2594355","DOI":"10.1080\/07853890.2025.2594355","volume":"57","author":"AS Albawa\u2019neh","year":"2025","unstructured":"Albawa\u2019neh AS, Alqasrawi MN, Al-Mahayri ZN, Albawaana A, Ahmed G, Al-Rifai RH, et al. Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis. Ann Med. 2025;57(1):2594355. https:\/\/doi.org\/10.1080\/07853890.2025.2594355. PubMed PMID: 41320800.","journal-title":"Ann Med"},{"key":"962_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1239335","author":"M Laakso","year":"2023","unstructured":"Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol. 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1239335.","journal-title":"Front Endocrinol"},{"key":"962_CR13","doi-asserted-by":"publisher","unstructured":"Zhang YY, Chen BX, Wan Q. Association of lipid-lowering drugs with the risk of type 2 diabetes and its complications: a mendelian randomized study. Diabetol Metabolic Syndrome. 2024;16(1). https:\/\/doi.org\/10.1186\/s13098-024-01477-8.","DOI":"10.1186\/s13098-024-01477-8"},{"key":"962_CR14","doi-asserted-by":"publisher","unstructured":"Sarsenbayeva A, Jui BN, Fanni G, Barbosa P, Ahmed F, Krist\u00f3fi R, et al. Impaired hmg-coa reductase activity caused by genetic variants or statin exposure: Impact on human adipose tissue, \u03b2-cells and metabolome. Metabolites. 2021;11(9). https:\/\/doi.org\/10.3390\/metabo11090574.","DOI":"10.3390\/metabo11090574"},{"key":"962_CR15","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S86013","author":"JP Kitzmiller","year":"2016","unstructured":"Kitzmiller JP, Mikulik EB, Dauki AM, Murkherjee C, Luzum JA. Pharmacogenomics of statins: Understanding susceptibility to adverse effects. Pharmacogenomics Personalized Med. 2016. https:\/\/doi.org\/10.2147\/PGPM.S86013.","journal-title":"Pharmacogenomics Personalized Med"},{"key":"962_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.125","author":"LB Ramsey","year":"2014","unstructured":"Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update. Clin Pharmacol Ther. 2014. https:\/\/doi.org\/10.1038\/clpt.2014.125.","journal-title":"Clin Pharmacol Ther"},{"key":"962_CR17","doi-asserted-by":"publisher","unstructured":"Saber-Ayad M, Manzoor S, El-Serafi A, Mahmoud I, Abusnana S, Sulaiman N. Statin-induced myopathy SLCO1B1 521T\u2009>\u2009C is associated with prediabetes, high body mass index and normal lipid profile in Emirati population. Diabetes Res Clin Pract. 2018;139. https:\/\/doi.org\/10.1016\/j.diabres.2018.03.014.","DOI":"10.1016\/j.diabres.2018.03.014"},{"key":"962_CR18","doi-asserted-by":"publisher","unstructured":"Kim TJ, Lee JS, Yoon JS, Oh MS, Kim JW, Park SH, et al. The Impact of Statin Treatment Duration on the Risk of New-Onset Diabetes Mellitus and Recurrent Vascular Events in Ischemic Stroke Patients: A Linked Data Analysis. Cerebrovasc Dis. 2025;54(2). https:\/\/doi.org\/10.1159\/000538485.","DOI":"10.1159\/000538485"},{"key":"962_CR19","doi-asserted-by":"publisher","unstructured":"Alqasrawi MN, Al-Mahayri ZN, Khasawneh LQ, AlBawa\u2019neh AS, Dabaghie L, Altoum SM, et al. A multi-centre observational cohort study on pharmacogenomic predictors of rosuvastatin discontinuation in a multiethnic population. Front Pharmacol. 2025;16. https:\/\/doi.org\/10.3389\/fphar.2025.1656520.","DOI":"10.3389\/fphar.2025.1656520"},{"key":"962_CR20","doi-asserted-by":"publisher","unstructured":"Al-Mahayri ZN, Khasawneh LQ, Alqasrawi MN, Altoum SM, Jamil G, Badawi S, et al. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Hum Genomics. 2022;16(1). https:\/\/doi.org\/10.1186\/s40246-022-00417-9.","DOI":"10.1186\/s40246-022-00417-9"},{"key":"962_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21176275.","journal-title":"Int J Mol Sci"},{"key":"962_CR22","doi-asserted-by":"publisher","unstructured":"Huang J, Lin H, Wang S, Li M, Wang T, Zhao Z, et al. Association between serum LDL-C concentrations and risk of diabetes: A prospective cohort study. J Diabetes. 2023;15(10). https:\/\/doi.org\/10.1111\/1753-0407.13440.","DOI":"10.1111\/1753-0407.13440"},{"issue":"10","key":"962_CR23","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.2337\/db19-1134","volume":"69","author":"YC Klimentidis","year":"2020","unstructured":"Klimentidis YC, Arora A, Newell M, Zhou J, Ordovas JM, Renquist BJ, et al. Phenotypic and genetic characterization of lower LDL cholesterol and increased type 2 diabetes risk in the UK biobank. Diabetes. 2020;69(10):2194\u2013205. https:\/\/doi.org\/10.2337\/db19-1134. PubMed PMID: 32493714.","journal-title":"Diabetes"},{"key":"962_CR24","doi-asserted-by":"publisher","unstructured":"Feng QP, Wei WQ, Chung CP, Levinson RT, Sundermann AC, Mosley JD, et al. Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Med. 2018;15(8). https:\/\/doi.org\/10.1371\/journal.pmed.1002642.","DOI":"10.1371\/journal.pmed.1002642"},{"key":"962_CR25","doi-asserted-by":"publisher","unstructured":"Andersson C, Lyass A, Larson MG, Robins SJ, Vasan RS. Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the Framingham Heart Study. Diabetologia. 2015;58(12). https:\/\/doi.org\/10.1007\/s00125-015-3762-x.","DOI":"10.1007\/s00125-015-3762-x"},{"key":"962_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.879355","author":"X Xiao","year":"2022","unstructured":"Xiao X, Luo Y, Peng D. Updated Understanding of the Crosstalk Between Glucose\/Insulin and Cholesterol Metabolism. Front Cardiovasc Med Front Media S A. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.879355.","journal-title":"Front Cardiovasc Med Front Media S A"},{"key":"962_CR27","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00410","author":"E Gendaszewska-Darmach","year":"2021","unstructured":"Gendaszewska-Darmach E, Garstka MA, B\u0142a\u017cewska KM. Targeting Small GTPases and Their Prenylation in Diabetes Mellitus. J Med Chem. 2021. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00410.","journal-title":"J Med Chem"},{"key":"962_CR28","doi-asserted-by":"crossref","unstructured":"Filippatos TD, Panagiotopoulou T, Tzavella E, Elisaf MS. Hypolipidemic Drugs and Diabetes Mellitus\u2014Mechanisms and Data From Genetic Trials. Journal of Cardiovascular Pharmacology and Therapeutics. SAGE Publications Ltd; 2018. pp. 187\u201391. doi:10.1177\/1074248418757011 PubMed PMID: 29409336.","DOI":"10.1177\/1074248418757011"},{"key":"962_CR29","unstructured":"Swerdlow DI, Preiss D, Swerdlow D. Genetic insights into statin-associated diabetes risk. Report."},{"issue":"13","key":"962_CR30","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jama.2016.14568","volume":"316","author":"LA Lotta","year":"2016","unstructured":"Lotta LA, Sharp SJ, Burgess S, Perry JRB, Stewart ID, Willems SM, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis. JAMA - J Am Med Association. 2016;316(13):1383\u201391. https:\/\/doi.org\/10.1001\/jama.2016.14568. PubMed PMID: 27701660.","journal-title":"JAMA - J Am Med Association"},{"issue":"22","key":"962_CR31","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/nejmoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375(22):2144\u201353. https:\/\/doi.org\/10.1056\/nejmoa1604304. PubMed PMID: 27959767.","journal-title":"N Engl J Med"},{"key":"962_CR32","doi-asserted-by":"publisher","unstructured":"SLCO1B1 Variants and Statin-Induced Myopathy \u2014 A Genomewide Study. N Engl J Med. 2008;359(8). https:\/\/doi.org\/10.1056\/nejmoa0801936.","DOI":"10.1056\/nejmoa0801936"},{"issue":"5","key":"962_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/cpt.2557","volume":"111","author":"RM Cooper-DeHoff","year":"2022","unstructured":"Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007\u201321. https:\/\/doi.org\/10.1002\/cpt.2557. PubMed PMID: 35152405.","journal-title":"Clin Pharmacol Ther"},{"key":"962_CR34","doi-asserted-by":"publisher","unstructured":"Lembo M, Trimarco V, Izzo R, Pacella D, Jankauskas SS, Gallo P, et al. Statin-induced risk of diabetes does not reduce cardiovascular benefits in primary prevention: a 6-year propensity-score matched study in a large population. Cardiovasc Diabetol. 2025;24(1). https:\/\/doi.org\/10.1186\/s12933-025-02798-2. PubMed PMID: 40450251.","DOI":"10.1186\/s12933-025-02798-2"},{"key":"962_CR35","doi-asserted-by":"publisher","unstructured":"Trimarco V, Izzo R, Gallo P, Manzi MV, Forzano I, Pacella D, et al. Long-Lasting Control of LDL Cholesterol Induces a 40% Reduction in the Incidence of Cardiovascular Events: New Insights from a 7-Year Study. J Pharmacol Exp Ther. 2024;388(3). https:\/\/doi.org\/10.1124\/jpet.123.001878.","DOI":"10.1124\/jpet.123.001878"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-026-00962-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-026-00962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-026-00962-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T22:49:57Z","timestamp":1779662997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40246-026-00962-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1186\/s40246-026-00962-7","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki and was approved by the Abu Dhabi Health Research and Technology Ethical Committee (Institutional Review Board - IRB) (Ref. DOH\/CVDC\/2020\/1187). All participants provided written informed consent before enrolment in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}